Sanjiv S. Agarwala, MD, chief of medical oncology and hematology, St. Luke’s Cancer Center, professor of medicine, Temple University School of Medicine, discusses the impact of entinostat for patients with melanoma who progress on a PD-1/PD-L1 blocking antibody.
Keith T. Flaherty, MD, director, Termeer Center for Targeted Therapy, Massachusetts General Hospital Cancer Center, professor of medicine, Harvard Medical School, discusses the tolerability of the combination of encorafenib (Braftovi) and binimetinib (Mektovi) in patients with melanoma.
Kenneth H. Shain, MD, PhD, assistant member, Moffitt Cancer Center, discusses novel agents in multiple myeloma.
Kendra Sweet, MD, an assistant member in the Department of Malignant Hematology at Moffitt Cancer Center, discusses discontinuation of tyrosine kinase inhibitor (TKI) therapy in chronic myeloid leukemia.
Andrew T. Kuykendall, MD, assistant member, Moffitt Cancer Center, discusses the impact of ruxolitinib (Jakafi) in myeloproliferative neoplasms (MPNs).
David A. Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, discusses the safety and efficacy data of an immunotherapy combination in glioblastoma.
Jarushka Naidoo, MBBCh, assistant professor of oncology, Johns Hopkins University, discusses the treatment of patients with non–small cell lung cancer who develop immune-related adverse events (irAEs).
Robert Coleman, MD, professor in the department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses the classification of patients with ovarian cancer.
Amit G. Singal, MD, associate professor, UT Southwestern Medical Center, discusses emerging systemic therapies in hepatocellular carcinoma.
Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses unmet needs in the treatment of patients with estrogen receptor (ER)-positive breast cancer.
Hak Choy, MD, Nancy B. & Jake L. Hamon Distinguished Chair in Therapeutic Oncology Research, Department of Radiation Oncology, UT Southwestern Medical Center, discuses therapy for patients with oligometastatic lung cancer.
Arlene O. Siefker-Radtke, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses next steps with erdafitinib in patients with bladder cancer.
Celeste Bello, MD, hematologist/oncologist, Moffitt Cancer Center, discusses investigational biomarkers in follicular lymphoma.
Paolo A. Ascierto, MD, director of the Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy at the National Tumor Institute Fondazione G. Pascale in Naples, discusses investigational triplet therapies in patients with BRAF-positive melanoma.
Lori J. Wirth, MD, associate professor of medicine, Harvard Medical School, medical director, Center for Head and Neck Cancers, Massachusetts General Hospital, discusses takeaways from the SELECT trial in patients with thyroid cancer.
Ian E. Krop, MD, PhD, chief, Breast Oncology, Susan F. Smith Center for Women’s Cancers, clinical research director, Breast Oncology Center, associate professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the impact of recent advances in breast cancer.
Jubilee Brown, MD, professor of gynecologic oncology, Levine Cancer Institute, Carolinas HealthCare System, discusses the importance of genetic testing in patients with ovarian cancer.
Richard F. Riedel, MD, associate professor of medicine, Duke Cancer Institute, discusses the treatment landscape of uterine sarcomas.
Shirley Michelle Shiller, DO, member of the Precision Medicine Institute's Advisory Committee, Baylor University Medical Center, discusses a patient’s hereditary predisposition to cancer.
Haythem Y. Ali, MD, senior medical oncologist, Henry Ford Hospital, discusses whether biosimilars can replace biologics in oncology.
Hans-Christian Kolberg, MD, head, Department of Obstetrics and Gynecology, Breast Cancer Center, and Gynecologic Cancer Center at Marienhospital Bottrop, Klinik für Gynäkologie und Geburtshilfe, Bottrop, Germany, discusses considerations for FDA-approved biosimilars.
David A. Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, discusses a personalized neoantigen-targeting vaccine for patients with glioblastoma.
Komal L. Jhaveri, MD, FACP, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses a basket trial of taselisib in patients with PIK3CA-mutated locally advanced or metastatic solid tumors.
Denise Yardley, MD, senior investigator, Sarah Cannon Research Institute, shares insight on the potential impact of biosimilars in breast cancer.
Nikhil C. Munshi, MD, director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses the role of checkpoint inhibitors in myeloma.
Zhaoming Wang, PhD, bioinformatics scientist, Department of Computational Biology, St. Jude Children’s Research Hospital, discusses a genomic analysis of breast cancer risk in pediatric cancer survivors.
Eric M. Ostertag, MD, PhD, chief executive officer, Poseida Therapeutics, Inc., discusses an emerging CAR T stem cell memory product for patients with relapsed/refractory multiple myeloma.
Martin Hutchings, MD, PhD, staff specialist, Department of Hematology, Finsen Centre, National Hospital, Copenhagen University Hospital, discusses a subgroup analysis of the ECHELON-1 study in Hodgkin lymphoma.
Douglas Yee, MD, professor of medicine and pharmacology, Hematology, Oncology and Transplant, medical oncologist, University of Minnesota, discusses the categorization of patients with triple-negative breast cancer.
Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses unmet needs in the treatment landscape of mantle cell lymphoma.
